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IMPROVED FATIGUE AND PHYSICAL FUNCTION ARE CORRELATED WITH
HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS SUBJECTS
TREATED WITH APREMILAST: RESULTS FROM A PHASE 2, RANDOMIZED,
CONTROLLED STUDY
Strand V1, Hu A2, Zhang F2
1Stanford University, Portola Valley, CA, USA, 2Celgene Corporation, Warren, NJ, USA
OBJECTIVES: Psoriatic arthritis (PsA) is an inflammatory arthritis with deleterious
effects on health-related quality of life (HRQOL). We evaluated the effect of apremi-
last (APR) on patient-reported outcomes (PROs) in PsA subjects and the correlation
between the 36-Item Short-Form Health Survey (SF-36) domains and disease-spe-
cific measures of physical function and fatigue.METHODS:A phase II, multicentre,
double-blind, placebo-controlled study randomised 204 subjects with active PsA
(duration 6 months; 3 swollen joints; 3 tender joints) 1:1:1 to oral APR 20mg
BID (APR20), 40mg QD (APR40), or placebo for 12 weeks. PROs included Functional
Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Health Assessment
Questionnaire–Disability Index (HAQ-DI), pain visual analogue scale (VAS), and
SF-36 domain scores. Correlations between the HAQ-DI, pain VAS, and FACIT-F and
the SF-36 Physical Function (PF), Bodily Pain (BP) and Vitality (VT) domains were
described with statistical significance. RESULTS: At week 12, mean change in PF,
BP, and VT was 2.1, 2.7, and 3.1 with placebo; 6.2 (P0.012 versus placebo), 11.5
(P0.001 versus placebo), and 6.6 (P0.05 versus placebo) with APR20; and 3.8, 7.9
(P0.037 versus placebo), and 3.7 with APR40, respectively. Mean change in HAQ-DI
was0.1,0.2, and0.2 with placebo, APR20, and APR40. Mean change in FACIT-F
was 0.5, 4.1 (P0.025), and 4.3 with placebo, APR20, and APR40. Mean percent
change in pain VAS was 7.4%,14.5%, and15.1% with placebo, APR20, and APR40.
Moderate (0.300.60) and statistically significant (P0.001) correlations were ev-
ident between pain VAS and BP (0.55), HAQ-DI and PF (0.43), and FACIT-F and VT
(0.55). High (0.60), statistically significant (P0.001) correlations were observed for
FACIT-F versus VT (0.66) with APR20 and HAQ-DI versus PF (0.73) with APR40.
CONCLUSIONS: Treatment of PsA with APR20 was associated with statistically
significant improvements versus placebo in FACIT-F and HRQOL. Moderate to high
correlations were evident among PROs.
PMS63
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OBJECTIVES: The PsAQoL is a measure of quality of life (QoL) specific to psoriatic
arthritis (PsA) first published in 2003. Content of the measure was derived entirely
from qualitative interviews conducted with UK PsA patients. New language ver-
sions have since been developed for several European countries, the US, Canada,
Argentina and Brazil. Interest in the PsAQoL has increased lately due to the need to
determine changes in QoL associated with new biological treatments. In recent
years there has been a move towards conducting clinical trials in developing coun-
tries. This has increased interest in adapting patient-reported outcome measures
developed in Europe and the United States for use in new regions of the World. An
important question remains to be answered; can such measures provide valid
assessment of QoL in these regions? METHODS: New adaptations are currently
being produced for Eastern Europe (4), the Middle East (2), Central and South Amer-
ica (2) and Asia (5). The measures are being translated (using the two panel meth-
odology required for needs-based measures) and tested with local patients by
means of cognitive debriefing interviews. RESULTS: To date cognitive debriefing
interviews have confirmed the adapted measures’ acceptability to patients who
found it easy to understand and complete. The adaptations also have good internal
consistency (alphas 0.85) and reproducibility (test-retest reliability coefficients:
0.85). The adaptations also exhibited construct validity by their ability to distin-
guish groups of PsA patients that varied by perceived disease severity and general
health and by correlating as expected (moderately) with the Nottingham Health
Profile. CONCLUSIONS: It is intended to use Item Response Theory analyses to
determine whether respondents in the developing countries answer the PsAQoL in
the same way as those in Western countries. This will show whether the scales
work validly in the developing countries.
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OBJECTIVES: To investigate whether patient reported outcomes in patients who
had been prescribed etanercept, an anti –TNF inhibitor, by their specialist could
detect changes in quality of life over time. A longitudinal evaluation was designed
to collect naturalistic data about their condition, medications and health care
experience. METHODS: The evaluation was conducted throughout the UK using a
web-based system supplemented by telephone reporting PROBE (patient reported
outcomes based evaluation). Outcome measures included demographic data, the
condition, previous treatment, current medications, patients’ experiences of their
condition, treatment and healthcare and quality of life. RESULTS: A total of 344
people participated in the evaluation at baseline, 290 online and 54 by telephone
with a mean age of 53 years and 62% female. 191 of these patients had Rheumatoid
Arthritis, 44 Psoriatic Arthritis, 43 Ankylosing Spondylitis, 35 psoriasis and 31 oth-
er/missing data. Patients were severely affected by their condition as noted on their
quality of life measures at baseline. Treatment had a marked beneficial effect for
patients as recorded by all measurement tools. All scores given in order. Baseline
month 6 mean (SD) clinical global impression 1 worst health 7 best health 3.15 (1.09)
to 4.31 (1.50) p0.001. EQ 5D Questionnaire 0.0 worst health 1.0 best health 0.39
(0.34) to 0.64 (0.27) p0.001. DLQI 30 worst effect 0 no effect on life 14.57 (6.74) to 3.69
(6.14) p0.001. HAQ. 0 no difficulty 3 unable to perform action 1.77 (0.63) to 1.25
(0.73) p0.001. CONCLUSIONS: This evaluation shows that patients have signifi-
cant impairment of their quality of life before commencing a biologic agent across
a range of conditions. Treatment with the biologic agent showed a sustained im-
provement in their quality of life up to 6 months. The PROBE methodology (web-
based system supplemented by telephone reporting) successfully captured
changes in patient reported quality of life measures.
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OBJECTIVES:Hip fracture is a major health burden in Thailand. We determined the
health-related quality of life for patients living with hip fracture, correlated factors
and relationships with one-year health care resource utilization. METHODS: A
self-administered Medical Outcomes Study 36-item Short Form Survey (MOS SF-36)
questionnaire was mailed to patient after hospital discharge over 6 months. A
cross-sectional analysis of MOS SF-36 was carried out among 119 hip fracture pa-
tients of Chiangrai Hospital. Healthcare resource utilization was follow-up for one
year taken from hospital database. RESULTS: Response rate was 67 % and a mor-
tality rate after one year was 14%. The Cronbach’s alpha coefficients of eight items
symptoms domain, and of two items of summary score components for physical
function and mental function of MOS SF-36 Thai questionnaire were 0.769 and
0.831 respectively. The mean SD (95 % CI) for summary score components for
physical and mental functions were 40.111.6 (38.0-42.2) and 48.010.2 (46.1-49.9)
respectively. There was no significant difference of mean SD scores for global
health between gender (p0.103), age (65 and 65years) (p0.798), BMI (20.0
and 20.0kg/m2) (p0.693), hip fracture management types (surgical and nonsur-
gical) (p0.386) and types of hip fracture (p0.188) respectively. Presence of co-
morbidity was a highly correlated factor for summary score components for phys-
ical (p0.030), and mental (p0.001) functions. There was no significant correlation
between overall one year healthcare resource utilization with both summary score
components for physical (p0.567) and mental (p 0.357) functions.
CONCLUSIONS:Health-related quality of life assessments with MOS SF-36 for Thai
hip fracture patients are reliable. Thai hip fracture patients reflect poorer physical
functions than mental functions. Presence of co-morbid disease is a factor well
correlated with poorer health-related quality of life. There is no significant corre-
lation between one-year health care resource utilization and health-related quality
of life for Thai hip fracture patients.
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OBJECTIVES: Hip fractures are traumatic and debilitating events which are more
common in the elderly, and associated with loss of mobility and independence,
mortality, and significantly increased health care resources. Our objectives were to
evaluate the impact of hip fractures on patients’ lives and summarise the patient
experience in a conceptual model. METHODS: Twenty-one adults aged 50 years
who experienced a hip fracture in the previous 2-18 months were recruited to
participate in in-depth semi-structured interviews exploring their experience of
hip fracture and impacts on their life. Thematic qualitative analysis of interview
transcripts was conducted using ATLAS.ti software to identify areas of impact
(concepts) and explore the interrelationships between concepts. A conceptual
model was developed based on this analysis. RESULTS: Participants were mostly
female (n12) with mean age 75 years (range 53-87 yrs), and 5 participants had a
hip fracture treated with partial or total hip replacement. Pain and limited mobility
were commonly reported by participants and were associated with increased phys-
ical inactivity. Mobility limitations included: difficulties walking (distance, speed,
up/down stairs), restricted or difficult lower limb movements, getting or standing
up and driving. Restrictions to various activities (everyday, physical, leisure and
social) were reported as well as wide-ranging impact on patients’ sleep, energy
levels, independence, emotions, family and other relationships. Moderators of the
impact of hip fracture on patients were also identified and incorporated into the
conceptual model. CONCLUSIONS: The conceptual model summarizes important
experiences and related impacts of hip fracture from the patient’s perspective and
demonstrates the wide-ranging effects in other areas of patients’ lives during their
recovery.
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